Waters Beats Q2, Lifts 2026 Outlook on Strong Lab and Diagnostics Demand
WAT sits 36% above its 52-week low of $275.05.
Summary
Waters delivered a clean beat-and-raise quarter. Q2 adjusted EPS of $3.05 topped the $3.01 consensus, and revenue of $1.65B exceeded the $1.62B estimate. The company raised its full-year 2026 adjusted EPS guidance to $14.45-$14.65 (from $14.40-$14.60) and revenue to $6.42B-$6.48B (from $6.41B-$6.46B), both above Street expectations. The recently acquired biosciences and diagnostics business from BD contributed $817M in its first full quarter, up 4% organically, while lab instrument sales rose 5% and consumables posted double-digit growth. This follows the earlier Dow Jones report highlighting 7%-9% organic revenue growth guidance, but today's release adds the actual Q2 beat and specific raised numbers. Q3 guidance of $3.95-$4.05 EPS and $1.75B-$1.76B revenue brackets consensus, suggesting momentum continues. The strong demand across lab equipment and diagnostics, combined with the successful integration of the BD assets, positions Waters for a solid year.
At the time of this announcement, WAT was trading at $373.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.8B. The 52-week trading range was $275.05 to $414.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.